mixed chimerism 5,6 and leukemic relapse, 7-10 especially in patients with chronic myelogenous leukemia (CML).
Summary: mixed chimerism 5, 6 and leukemic relapse, 7-10 especially in patients with chronic myelogenous leukemia (CML).
Based on previous experiences in animals and humans,
The role of the T cell subpopulations in aGVHD, graftlow doses of CD8
+ lymphocytes infused together with versus-leukemia (GVL) effect and graft failure has been the marrow graft seem to enhance engraftment after studied in experimental animal models and in clinical proallogeneic T cell-depleted marrow transplantation.
tocols of selective T cell depletion. [11] [12] [13] [14] It is accepted that From April 1994 to February 1997, 12 patients with both CD4 + and CD8 + lymphocytes are involved in the allochronic myelogenous leukemia in first chronic phase reactive response after BMT, causing aGVHD. 15 Selective receiving a bone marrow transplant (BMT) from an depletion of CD8 + cells from the marrow graft in combi-HLA-identical sibling were included in a pilot study of nation with in vivo cyclosporin A induces a low rate of T cell subset depletion. Total depletion of CD4
+ cells of GVHD with about 10% of graft failure after BMT using the marrow graft and partial depletion of CD8 + cells HLA-identical sibling donors. [16] [17] [18] [19] Depletion of both CD4 + was performed by immunomagnetic separation. In and CD8 + cells leads to a low rate of aGVHD even in unorder to improve the engraftment rate, we infused a low related donor BMT, but leukemic relapse still remains a fixed number of CD8 + lymphocytes (0.25 × 10 6 /kg). All problem.
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the patients were at high risk of developing acute graftIn animal models, it has been postulated that CD8 + cells versus-host disease (GVHD), with a recipient age of Ͼ30 may be important to ensure engraftment after BMT. 21 years, and/or donor sensitized by previous pregnancies Moreover, patients transplanted using a low fixed number or transfusions. All of them received cyclosporin A and of lymphocytes in the graft after physical depletion of T methotrexate post-BMT. No graft failure was observed.
cells showed a stable and durable engraftment in the The grade III-IV GVHD rate was 16.6%, and the actumajority of cases, with an effective prevention of arial survival at 3 years is 81.8%. Immunological recovaGVHD. 22, 23 ery showed persistent CD8 + HLA-DR + lymphocytosis 8 We have developed a program of allogeneic bone marmonths after transplant. Relapses were not observed.
row transplantation for patients with CML and with high This experience shows the importance of CD8 + cells to risk of aGVHD, using selective depletion of T cell subsets, ensure correct engraftment, decreasing the GVHD rate.
by total immunomagnetic CD4 + depletion and partial CD8 + Keywords: T cell subset depletion; CD8 + lymphocytes; depletion. We infused a low fixed number of CD8 + cells GVHD prevention; graft failure with the graft to attempt an effective prevention of aGVHD, ensuring engraftment and without increasing the rate of leukemic relapses. We have previously reported 24, 25 our initial experience Acute graft-versus-host disease (aGVHD) is an important cause of morbidity and mortality after allogeneic bone marin adult patients with hematological malignancies receiving row transplantation (BMT) despite the use of several a transplant from an unrelated donor or from a HLA-identimmunosuppressive agents. 1 Exhaustive T cell depletion of ical sibling at high risk of GVHD, using 1 ϫ 10 6 CD8 + the marrow graft by physical 2 or immunologic 3 methods cells/kg in the graft, and post-BMT prophylaxis with cyclois the most effective method to prevent aGVHD, but it is sporin A, short course of methotrexate (four doses) and associated with an increased incidence of graft failure, plant-related mortality was high, mostly due to infectious irradiation (TBI), 1350 cGy divided over 3 to 5 days. Six patients received ATG 30 mg/kg daily, days −6, −5 and −4. episodes.
In order to ameliorate these results, we started a pilot study in patients with CML in first chronic phase receiving
Patient management an allogeneic transplant from a HLA-identical sibling, at high risk of aGVHD, infusing a lower dose of CD8 + cells Patients were nursed either in individual rooms with HEPA in the graft (0.25 ϫ 10 6 /kg), maintaining post-BMT GVHD filters or in laminar air-flow rooms, and received antibiotic prophylaxis with cyclosporin A and methotrexate, but withprophylaxis with oral quinolones plus acyclovir (200 out prophylactic prednisone, to avoid the steroid-related mg/m 2 /8 h from day +1 to day +35 or 500 mg/m 2 /8 h from infectious complications. The aim of this study was to day -7 to day +28. Intravenous human immunoglobulin was evaluate the engraftment rate, GVHD incidence, relapses, administered weekly at dose of 100 mg/kg until day +100. immunological recovery and overall survival.
Pharmacological prophylaxis of aGVHD was performed in all cases with cyclosporin A (initial dose: 5 mg/kg/daily in 10-h infusion, from day -1, with determination of serum Patients and methods levels and maintenance between 250-400 ng/ml) and methotrexate (15 mg/m 2 day +1, and 10 mg/m 2 days +3, Inclusion criteria +6 and +11). CMV infection was followed by detection of antigenemia, and gancyclovir was started if antigenemia CML patients in first chronic phase were included in the was positive. No CMV negative blood products were used. study when they had an HLA-identical sibling donor for allogeneic BMT, and at least one of two risk factors for aGVHD was present: (1) recipient age Ͼ30 years old; 26 or Definitions (2) donor sensitized by previous pregnancies or trans-
The day of engraftment was defined as the day when neufusions. 27, 28 All the patients had normal pulmonary, cardiac trophils were Ͼ500/mm 3 . The recovery of platelets was and hepatic functions. Patients younger than 18 years old considered when platelets were Ͼ20 ϫ 10 9 /ml without supwere excluded from this protocol.
port. Patients were evaluated for acute GVHD when they had engraftment and were alive beyond day +30. Chronic Patients GVHD was evaluated when the patient was alive beyond day +100. Diagnosis of aGVHD was scored according to From April 1994 to February 1997, 12 CML patients were established criteria 29 until patient's discharge, last examinincluded in this clinical assay, in two hospitals: six patients ation or death. All skin rashes were biopsied. Intestinal at the Duran i Reynals Hospital, and six at the Santa Creu aGVHD was confirmed by rectoscopy and rectal biopsy, i Sant Pau Hospital, Barcelona, Spain. All patients gave and in some cases, hepatic aGVHD was confirmed by a informed consent to be included in the protocol. Charactertransjugular liver biopsy. istics of the patients are listed in Table 1 . Median age was 41.4 years (range: 29-50). All of them received marrow grafts from a HLA-identical sibling. HLA typing was per-T cell depletion of the graft formed by serology for HLA-A and -B loci, and by PCR-SSP for HLA-DRB1. Five patients had one of two risk fac-
The working buffer used during the whole purging procedure consisted of saline containing 1% human serum tors for aGVHD (recipient age greater than 30 years, or donor sensitized by previous pregnancies or transfusions).
albumin, penicillin 100 units/ml and streptomycin 100 g/ml (not used in patients known to be allergic to these Seven patients had both risk factors.
The conditioning regimen consisted of cyclophosphamantibiotics), and buffered with sodium bicarbonate (saline-HSA). Freshly aspirated marrow mononuclear cells (MNC) ide (60 mg/kg/daily for 2 consecutive days) and total body 
, and CD8 + in CD3 Ϫ cells; further manipulation. The rest of the marrow was processed as described for the first stage, using an anti-CD8 MoAb and (4) B cell recovery by expression of CD19, and coexpression of CD19 and CD5 (immature B cells). (51.1), and Dynabeads M-450 SAM at a bead:target-cell ratio of 20:1. After flow cytometry controls to ensure the CD8 depletion, the two fractions were combined to infuse a Statistical analysis fixed number of CD8 + lymphocytes/kg. Prior to the marrow infusion into the patient, aliquots for microbiological study Actuarial survival curves were calculated using the KaplanMeier method. 30 and flow cytometry were taken. The total volume of the infusion was approximately 150 ml.
Results

Flow cytometry
Analysis of CD4
+ and CD8 + lymphocyte depletion: aliquots T cell depletion procedure obtained from MNC after density gradient separation, CD4 + After Ficoll separation, the median number of mononuclear lymphocyte-depleted cell fraction and final CD4 + /CD8 + cells in the graft was 6.28 ϫ 10 7 /kg recipient body weight lymphocyte-depleted cell fraction. Samples were incubated (range: 3.3-12), and after all the procedures, the number with anti-CD34 (MPCA-2; Becton Dickinson, San Jose, of mononuclear cells infused was 2.82 ϫ 10 7 /kg recipient CA, USA), anti-CD3 (Coulter, Hialeah, FL, USA), antibody weight (1.25-7.63). CD4 (Coulter) and anti-CD8 (Coulter) according to the The percentage of CD4 + cells was reduced from 18.5% manufacturer's instruction. Samples were washed in PBS (9-26) to 0.01% (0-0.6), and the percentage of CD8 + cells and lysed by incubation with 1 ml of Ortho-Mure Lysing from 13.5% (6.6-22.8) to 0.3% (0.01-1.4). This represents Reagent (Ortho, Raritan, NJ, USA) for 10 min at room a purging efficiency of 3.11 log (1.71-3.63) for CD4 + cells temperature, and washed in PBS. Appropriate isotypic and 1.92 log (1.08-3.13) for CD8 + cells. In one patient, due irrelevant MoAbs were used as negative controls.
Data acquisition was performed by flow cytometry in an to technical problems, the dose of CD8 + cells infused was Survival 0.5 ϫ 10 6 /kg. Table 2 summarizes the effectiveness of the The actuarial survival at 3 years is 81.8% (Figure 1 ). Only immunomagnetic depletion.
two patients died, on days +61 and +72, due to acute GVHD in one case, and due to fungal infection with CNS involvement in the other. All the patients are free of disEngraftment ease, and the actuarial disease-free survival curve (at the All the patients engrafted and no late graft failure was clinical and the molecular level) is the same as the overall observed. The median time to granulocyte count recovery survival curve. Ͼ0.5 ϫ 10 9 /l was 22.5 days (range: 14-28), and the median time to platelet recovery of Ͼ20 ϫ 10 9 /l without support Immunological reconstitution was 32 days (range: 15-92) from bone marrow infusion. We did not observe any difference in the kinetics of The lymphocyte reconstitution in peripheral blood was folengraftment, incidence of aGVHD or relapses between lowed monthly in six patients, at least during the first 4 patients who received ATG previously to transplant and months after BMT. The more interesting observations are those that did not receive ATG.
as follows.
T lymphocyte subpopulations:
The total percentage of lymGraft-versus-host disease phocytes in peripheral blood was within the range of normality by the second month post-BMT, reaching supranorTwo patients remained free of aGVHD. Two patients mal values from the third to the eighth month. The developed aGVHD grade I, six patients developed grade II, percentage of T lymphocytes (CD3 + ) as well as the total and two patients developed aGVHD grade III. No grade IV number, was in the normal range within the first 5 months aGVHD was seen. The overall grades III-IV aGVHD was 16.6%. All but one patient responded to steroid treatment.
Nine patients were evaluable for chronic GVHD. Three 
post-transplant. The percentage of CD4
+ lymphocytes was Discussion always very low, and it was still below the normal range
In this study, we did not see any case of graft failure, sugat 8 months post-BMT. By contrast, the percentage of the gesting that the infusion of a fixed low number of CD8
+ subpopulation (cytotoxic/suppressor) was norcells is enough to ensure correct engraftment. Hematologmal at the time of the engraftment, increasing the percentical recovery was in the normal range after allogeneic transage after the second month, reaching 80-90% of the T cells plants. The incidence of aGVHD grade III-IV was 16.6%. in peripheral blood at 8 months post-transplant (Figure 2a) . This was higher than the incidence observed in other studThe CD4:CD8 ratio decreased during the first 3 months ies that use a broad T cell depletion, however, the patients post-transplant, and remained inverted (Ͻ0.25) (Figure 2b) . included in this protocol were all at high risk of aGVHD The percentage of minority T lymphoid subpopulations and they were all adult patients, with a median age of 41.4 CD3 + CD4 Ϫ CD8 Ϫ and CD3 + CD4 + CD8 + was in the noryears. The risk of aGVHD in bone marrow transplantation mal range during the analysis. from a HLA-identical sibling donor is influenced by factors such as the age of the recipient and previous sensitization of Activation markers: Expression of CD38 and HLA-DR on the donor by pregnancy or blood transfusions. In an HLA-T lymphocytes was high since the engraftment. Percentage identical model, the role of the minor histocompatibility of HLA-DR + cells increased progressively during the 8 antigens is important in the pathogenesis of aGVHD, as months analyzed, as well as the CD8 cells. CD38
Goulmy et al described.
31 expression on T cells was lower than HLA-DR expression, Previous experiences with T cell subset depletion has and its overexpression was only detected in the first months shown that total depletion of CD8 + cells is associated with after BMT (Figure 2c) . Hypothetically, this CD8
+ DR + lyma lower incidence of aGVHD, but also 10% graft failure phocytosis could be responsible for a certain GVL effect.
and 10% leukemic relapse. [16] [17] [18] [19] This, in addition to our results, suggests that CD8 + cells are important to ensure NK population: The percentage of NK cells was normal engraftment, probably through an immediate immunologsince the engraftment. The predominant subpopulation in ical effect against the residual T lymphocytes of the recipinormal individuals, CD3
Ϫ CD56 + CD16 + was always overent. Experiences with murine models support the hypothexpressed at the engraftment, but from the second to the esis that this effect could be mediated through a veto fourth month, the predominant subpopulation was CD3 Ϫ mechanism of CD8 + cells. 32 On the other hand, the effect of CD56 + CD16 Ϫ (Figure 3 ). The subpopulation CD3
Ϫ CD8 + cells on engraftment may act via cytokine production. CD56 Ϫ CD16 + was also into the normal range. We did not observe any relapse. despite having only a median follow-up of 1.5 years, the relapse rate seems to be very low in these patients, in contrast to the transplants B lymphocytes: The expression of CD19 was below the normal values during all the study. The coexpression of performed with exhaustive T cell depletion, especially in patients with CML. 33, 34 The experiences of Verdonck et CD5 in CD19
+ cells (naive B cells) was very high at the engraftment, with gradual decrease and normalization at 5 al 22, 23 using a low fixed number of T lymphocytes after T cell depletion by soybean lectin agglutinin show similar months post-BMT. after bone marrow transplantation, 40 and it has been postu- reported. 41 27-42.
In conclusion, this approach to T cell subset depletion 
